User menu

Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy.

Bibliographic reference Maloteaux, Jean-Marie ; Laterre, Emile-Christian ; Laduron, P M ; Javoy-Agid, F ; Agid, Y.. Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy.. In: Movement disorders : official journal of the Movement Disorder Society, Vol. 3, no. 3, p. 255-62 (1988)
Permanent URL http://hdl.handle.net/2078.1/11739
  1. Leysen, Nature, 272, 168 (1978)
  2. Peroutka, Mol Pharmacol, 16, 687 (1979)
  3. Leysen, Mol Pharmacol, 21, 301 (1982)
  4. Schotte, Brain Res, 276, 231 (1983)
  5. Hoyer, Brain Res, 376, 97 (1986)
  6. Receptors in human brain: from regional distribution to molecular characterization. In: eds. The role of receptors in biology and medicine. New York: Raven Press, 1986: 186-92.
  7. Reynolds, Neurosci Lett, 44, 47 (1984)
  8. Cross, J Neurochem, 43, 1574 (1984)
  9. Rossor, Br Med Bull, 42, 70 (1986)
  10. Quirion, Brain Res, 333, 345 (1985)
  11. Scatton, Brain Res, 275, 321 (1983)
  12. Hardy, Neurochem Int, 7, 545 (1985)
  13. Bowen, J Neurochem, 41, 266 (1983)
  14. Raisman R, Cash R, Agid Y, Parkinson's disease: decreased density of 3H-imipramine and 3H- paroxetine binding sites in putamen, 10.1212/wnl.36.4.556
  15. Cash, Eur J Pharmacol, 117, 71 (1985)
  16. Maloteaux, J Neurol [Suppl], 32, 108 (1985)
  17. Dementia in Parkinson's disease. In: eds. Handbook of psychopharmacology. New York: Plenum Press (in press). (Psychopharmacology of the ageing nervous system, vol 20).
  18. Boller, Ann Neurol, 7, 329 (1980)
  19. Albert, J Neurol Neurosurg Psychiatr, 37, 121 (1974)
  20. Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: eds. Parkinson's disease. New York: Raven Press, 1987: 191-204. (Advances in neurology, vol 45).
  21. Anatomoclinical and biochemical concepts of subcortical dementia. In: eds. Congnitive neurochemistry assessment techniques and research strategies for understanding the pharmacologic basis of human neuropsychology. London: Oxford University Press (in press).
  22. Dubois, Brain Res, 288, 213 (1983)
  23. Ruberg, Brain Res, 232, 129 (1982)
  24. Ruberg, Ann Neurol, 18, 523 (1985)
  25. Mayeux R., Stern Y., Rosen J., Leventhal J., Depression, intellectual impairment, and Parkinson disease, 10.1212/wnl.31.6.645
  26. Mayeux R., Stern Y., Cote L., Williams J. B.W., Altered serotonin metabolism in depressed patients with Parkinson's disease, 10.1212/wnl.34.5.642
  27. Perry, Neurosci Lett, 51, 353 (1984)
  28. Perry, J Neurol Neurosurg Psychiatry, 48, 413 (1985)
  29. Rossor, Neurosci Lett, 20, 373 (1980)
  30. Epelbaum, Brain Res, 278, 376 (1983)
  31. Arai, J Neurochem, 43, 388 (1984)
  32. Brain somatostatin concentrations do not decrease in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (in press).
  33. The effects of drugs on serotonin-mediated behavioural model. In: ed. Neuropharmacology of serotonin. Oxford: Oxford University Press, 1985: 326-65.
  34. Van Praag, Lancet, 2, 1259 (1983)
  35. Stanley, Lancet, 1, 214 (1983)
  36. Owen, Lancet, 1, 1256 (1983)
  37. Mita, Biol Psychiatry, 21, 1399 (1986)